By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
AdkhabarAdkhabarAdkhabar
Notification Show More
Font ResizerAa
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Reading: Texas Cardiac Arrhythmia Institute at St. David’s Medical Center first in U.S. to implant FDA-approved novel defibrillation lead
Share
Font ResizerAa
AdkhabarAdkhabar
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Search
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Follow US
Adkhabar > Blog > News > Texas Cardiac Arrhythmia Institute at St. David’s Medical Center first in U.S. to implant FDA-approved novel defibrillation lead
Texas Cardiac Arrhythmia Institute at St. David’s Medical Center first in U.S. to implant FDA-approved novel defibrillation lead
News

Texas Cardiac Arrhythmia Institute at St. David’s Medical Center first in U.S. to implant FDA-approved novel defibrillation lead

Last updated: 02/02/2026 12:36 PM
Published: 02/02/2026
Share
SHARE

The new technology is the world’s smallest, catheter-delivered defibrillation lead

- Advertisement -

AUSTIN, Texas, Feb. 2, 2026 /PRNewswire/ — Electrophysiologists at the Texas Cardiac Arrhythmia Institute (TCAI) at St. David’s Medical Center recently became the first in the nation to implant an FDA-approved novel defibrillation lead—a specialized, insulated wire that connects to an implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT-Ds) device to the heart and corrects abnormal rhythm. The defibrillation lead is the world’s smallest, catheter-delivered defibrillation lead, which allows for precise delivery and placement in the right ventricle.

- Advertisement -

The first procedure was performed by Robert Canby, M.D., and Amin Al-Ahmad, M.D., clinical cardiac electrophysiologists at TCAI, on Jan. 7. Dr. Canby also participated in the trial that led to FDA approval.

- Advertisement -

“When treating patients, safety and efficacy are paramount, and this novel technology allows us to achieve both with greater precision,” said Andrea Natale, M.D., F.H.R.S., F.A.C.C., F.E.S.C., cardiac electrophysiologist and executive medical director of TCAI. “This milestone is a testament to the Texas Cardiac Arrhythmia Institute’s continued pursuit of innovation that will improve outcomes and access to life-saving care.”

- Advertisement -

A lead senses the heartbeat and transmits signals to the implanted device, which then delivers therapy to correct or interrupt abnormally fast rhythms—called arrhythmias—that can result in sudden cardiac arrest. Existing defibrillation leads are larger in diameter, increasing the potential for future complications.

- Advertisement -

According to the Journal of the American Heart Association, an estimated 12.1 million people in the U.S. are expected to have atrial fibrillation—the most common arrhythmia—by 2030.

- Advertisement -

TCAI is a state-of-the-art Electrophysiology Center that includes six labs equipped with advanced technology where a group of esteemed cardiac electrophysiologists—led by Dr. Natale, a world-renowned expert in the field—perform a high volume of the most complex electrophysiology procedures.

- Advertisement -

View original content:https://www.prnewswire.com/in/news-releases/texas-cardiac-arrhythmia-institute-at-st-davids-medical-center-first-in-us-to-implant-fda-approved-novel-defibrillation-lead-302675495.html

- Advertisement -
NYSE Content Advisory: Pre-Market update + Block Exceeds $200 Billion in Credit Provided to Its Users
Dubai Municipality unveils Circle Dubai project championing Sustainability and Waste Reduction at Asia-Pacific Cities Summit
InspireSemi Provides Administrative Updates
DeepHealth Unveils Next-Generation Imaging Informatics and Clinical AI Solutions at RSNA 2025, Advancing a New Standard of AI-Powered Care
InnoCare Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Marginal Zone Lymphoma in Singapore
TAGGED:arrhythmiacardiaccenterdavid’sdefibrillationfda-approvedfirstimplantinstituteleadmedicalnewsnovelst.texasu.s.
Share This Article
Facebook Email Print
- Advertisement -

Follow US

Find US on Social Medias
FacebookLike
XFollow
YoutubeSubscribe

Weekly Newsletter

Subscribe to our newsletter to get our newest articles instantly!
Popular News
IBA Launches myQAMatriXXAiR to Advance PatientSpecific QA in Particle Therapy
Health

IBA Launches myQAMatriXXAiR to Advance PatientSpecific QA in Particle Therapy

GlobeNews Wire
GlobeNews Wire
21/03/2026
VT Markets launches brand film to showcase shared values with NUFC to mark the beginning of the partnership’s second year
IMG Ranked Best Travel Insurance Company of 2026 by Forbes Advisor
Axtria Acquires Conexus Solutions, Uniting Agentic AI and CRM Mastery to Redefine Life Sciences Commercialization
James Cacioppo Files Updated Early Warning Report
- Advertisement -
- Advertisement -
- Advertisement -

Categories

  • Automobile
  • Entertainment
  • E-Sports
  • Food
  • Health
  • Technology
  • LifeStyle
  • Travel

About Us

Through our news networks, we raise millions of users' awareness. We are among the world's most reputable news networks.
Quick Link
Top Categories
  • Entertainment

Subscribe US

Subscribe to our newsletter to get our newest articles instantly!

AdkhabarAdkhabar
Copyright © 2021 - 2025 AdKhabar. All Rights Reserved. POWERED BY Life Care News.
Join Us!
Subscribe to our newsletter and never miss our latest news, podcasts etc..
Zero spam, Unsubscribe at any time.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?